Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Human transcription and processing
- Types of non-coding RNAs
- Part I - MicroRNAs
- miRNA biogenesis
- miRNA biogenesis and cancer
- miRNAs are implicated in several cancers
- Application of miRNAs in cancer
- Role of miRNAs in cancer: as biomarkers
- miRNAs as diagnostic markers
- miRNAs as prognostic markers
- miRNAs as predictive markers
- MiRNA polymorphisms (miR-SNPs) in cancer
- miR-SNPs in cancer - clinical trials
- Role of miRNAs in cancer: as therapeutic agents
- Strategies to inhibit Onco-miRs - Anti miRs
- Antisense oligonucleotides
- Strategies to inhibit Onco-miRs - Small molecules
- Strategies to inhibit Onco-miRs - miRNA sponges
- Strategies to restore TS-miRs - miRNA mimics
- Strategies to restore TS-miRs
- Delivery system for miRNA therapeutics - GalNac
- Delivery system for miRNA therapeutics - EDV
- Clinical development of miRNA therapeutics
- Part II - long non-coding RNAs (lncRNAs)
- The diversity of lncRNAs
- LncRNAs are implicated in several cancers
- LncRNAs - cancer-associated pathways
- Application of lncRNAs in cancer
- Role of lncRNAs in cancer: as biomarkers
- Role of lncRNAs in cancer: gene biomarker lists
- LncRNAs as risk markers
- LncRNAs as risk markers - PACT1 enhancer
- LncRNAs as risk markers - CCAT2
- LncRNAs as diagnostic & prognostic markers
- LncRNAs as diagnostic markers
- LncRNAs as prognostic markers - NKILA
- LncRNAs as prognostic markers - A12-LncRNA
- LncRNAs as predictive markers - CCAT1
- LncRNAs as predictive markers - LINK-A
- LncRNAs currently in clinical trials as biomarkers
- Role of lncRNAs in cancer: as therapeutic agents
- Challenges of targeting lncRNAs
- Take home messages
Topics Covered
- Types of non-coding RNAs
- Role of microRNAs and long non-coding RNAs in cancers
- Recent advances in strategies to utilize miRNAs and lncRNAs as biomarkers in cancer
- miRNAs and lncRNAs are currently in clinical development as diagnostic, prognostic and predictive biomarkers for cancer
- Recent advances in strategies to utilize miRNAs and lncRNAs as therapeutic targets in cancer
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Calin, G. and Shah, M. (2018, February 28). Recent advances in the field of non-coding RNAs in cancer [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/JOJJ9323.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. George Calin has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
- Dr. Maitri Shah has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Series: Periodic Reports: Advances in Clinical Interventions and Research Platforms
Transcript
Please wait while the transcript is being prepared...
0:00
Hello everyone, I am Maitri Shah,
I'm a Postdoctoral Fellow in Dr. George Calin's lab
at MD Anderson Cancer Center in Houston, Texas.
Today, I'll be talking about
the recent advances in the field of non-coding RNAs in cancer,
particularly those in the last two years
that have influenced research and clinical practice.
0:21
Integrated use of advanced genome analysis platforms in recent years by consortia
such as the Human Genome Project and the Encyclopedia of DNA Elements or ENCODE Project,
have revealed that the transcription and processing of
the human genome yields a diverse catalog of non-coding RNAs.
The protein-coding genes occupy less than two percent of the human genome.
These protein-coding genes account for approximately one-third of all annotated genes;
whereas, long and small non-coding RNAs genes,
together account for 40 percent of the genes.
Considering their ubiquitous presence and diversity,
these non-coding RNAs have attracted a lot of attention in the past decade and
extensive research has been performed to understand
their role in normal cellular physiological processes,
as well as in human diseases.
1:15
Non-coding RNAs are arbitrarily classified into
short and long non-coding RNA based on the transcript size.
Small non-coding RNAs are shorter than 200 nucleotides.
This category includes microRNAs,
endogenous small interfering RNAs or siRNAs,
small nucleolar RNAs or snoRNAs,
and PIWI-interacting RNAs or piRNAs.
Long non-coding RNAs are longer than 200 nucleotides
and include long intergenic non-coding RNAs or lincRNAs,
natural antisense transcripts or NATs,
transcribed ultra-conserved regions or T-UCRs,
long enhancer non-coding RNAs,
non-coding repeat sequences, and pseudogenes.
First, I would like to talk about microRNAs,